Charles F. Wagner, Jr
2021
In 2021, Charles F. Wagner, Jr earned a total compensation of $6.2M as EVP & Chief Financial Officer at Vertex Pharmaceuticals, a 2% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,078,539 |
|---|---|
| Salary | $729,615 |
| Stock Awards | $4,375,430 |
| Other | $40,348 |
| Total | $6,223,932 |
Wagner received $4.4M in stock awards, accounting for 70% of the total pay in 2021.
Wagner also received $1.1M in non-equity incentive plan, $729.6K in salary and $40.3K in other compensation.
Rankings
In 2021, Charles F. Wagner, Jr's compensation ranked 2,033rd out of 12,397 executives tracked by ExecPay. In other words, Wagner earned more than 83.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,033 out of 12,397 | 84th |
Division Manufacturing | 776 out of 5,492 | 86th |
Major group Chemicals And Allied Products | 303 out of 2,367 | 87th |
Industry group Drugs | 262 out of 2,090 | 88th |
Industry Pharmaceutical Preparations | 170 out of 1,537 | 89th |
Source: SEC filing on April 7, 2022.
Wagner's colleagues
We found four more compensation records of executives who worked with Charles F. Wagner, Jr at Vertex Pharmaceuticals in 2021.